Smoking Cessation in Rural Hospitals

Smoking Cessation Clinical Trial

Official title:

Centralized Disease Management for Rural Hospitalized Smokers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01063972
• Other study ID #: 5R01CA101963-07
• Secondary ID: 5R01CA101963-07
• Status: Completed
• Phase: N/A
• Start date: March 2010
• Est. completion date: February 2015

Study information

• Verified date: April 2019
• Source: University of Kansas Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Our long-term goal is to improve smoking cessation treatment for rural smokers. The objective is to assess the effectiveness of a centralized disease management program for hospitalized smokers that coordinates care across treatment settings and links smokers to existing resources. Our central hypothesis is that Centralized Disease Management (CDM) will increase the use of smoking cessation treatments and lead to greater long term smoking cessation than Counseling alone. Demonstrating the effectiveness of a disease management program and identifying the critical components of such a program will provide a basis for improving the utilization of existing smoking cessation resources while enhancing the treatment of rural hospitalized smokers.

Description:

The proposed study will use a randomized clinical trial design to examine the effectiveness of centralized disease management (CDM) versus counseling alone (C) for smoking cessation. Hospitalized smokers in 30 rural critical access hospitals will be randomly assigned to either CDM (n=303) or C (n=303). Participants in both arms of the study will receive in-hospital smoking cessation counseling via telephone followed by 4 outpatient telephone-based counseling calls. The content and timing of these counseling calls are designed to emulate models of smoking cessation counseling that have been previously shown to be effective for hospitalized smokers. For recipients assigned to CDM, the counseling will be streamlined to allow time on the calls for specific disease management interventions, including screening for contraindications to pharmacotherapy and linking medication choices to the smoker's insurance coverage. After completing calls with CDM participants, the Tobacco Treatment Specialists will coordinate therapy with the patient's health care providers by providing them with brief consultation reports, prepared order sheets for inpatient treatment, and outpatient prescription requests. Six months postdischarge, participants in both groups will be contacted again, and persistent or relapsed smokers will be offered another cycle of the C or CDM intervention.

Assessments will be conducted at baseline and at months 3, 6, and 12. The primary outcome of interest will be biochemically verified 7-day point prevalence abstinence at 12 months. Secondary endpoints include number of quit attempts and number of cigarettes smoked (among continuing smokers), pharmacotherapy utilization, duration of pharmacotherapy utilization, and the extent of discussions with the healthcare provider. We will also examine the marginal cost-effectiveness of the intervention.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 606
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Hospitalized in a participating rural hospital

• Aged 18 years or older

• Smoke cigarettes on >25 of the last 30 days

• Have a home address and telephone

• Willing to participate in phone assessments

Exclusion Criteria:

• Terminal medical condition with life expectancy <1 year

• Pregnant

Related Conditions & MeSH terms

• Smoking Cessation

Intervention

Behavioral:
• Centralized disease management (CDM)
Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider
• Counseling (C)
Counseling (C) arm will receive counseling without the care coordination services.

Locations

Country	Name	City	State
United States	University of Kansas Medical Center	Kansas City	Kansas

Sponsors (2)

Lead Sponsor	Collaborator
Edward Ellerbeck, MD, MPH	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With 7-day Point Prevalence Abstinence From Cigarettes, Validated	Participant-reported 7-day point prevalence abstinence from cigarettes, validated by salivary cotinine (< 15ng/ml) or proxy. Participants who did not respond to the survey were considered current smokers.	12 months
Secondary	Number of Participants With 7-day Point Prevalence Abstinence at 3 Months, Self-reported	7-day point prevalence abstinence at 3 months, self-reported. Participants who did not respond were considered smokers.	3 months
Secondary	Number of Participants With 7-day Point Prevalence Abstinence at 6 Months, Self-reported	7-day point prevalence abstinence at 6 months, self-reported. Participants who did not respond were considered smokers.	6 months
Secondary	Number of Participants With 7-day Point Prevalence Abstinence at 12 Months, Self-reported	7-day point prevalence abstinence at 12 months, self-reported. Participants who did not respond were considered smokers.	12 months
Secondary	Number of Participants Reporting Utilization of Smoking Cessation Pharmacotherapy During First 6 Months		6 months
Secondary	Number of Participants Reporting Utilization of Smoking Cessation Pharmacotherapy Between 6 and 12 Months		12 months